Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.PharmacoEconomics · 2018
   Pooled it
2. Evaluation of statin utilization in the Republic of Macedonia during 2013-2016.ClinicoEconomics and outcomes research : CEOR · 2018
   Article
3. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.BMC medicine · 2014
   Article
4. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.Frontiers in pharmacology · 2014
   Review
5. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Frontiers in pharmacology · 2013
   Article
6. Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.Frontiers in pharmacology · 2012
   Article
7. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Pharmaceuticals (Basel, Switzerland) · 2010
   Review
8. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.BMC health services research · 2010
   Review
9. Policies to enhance prescribing efficiency in europe: findings and future implications.Frontiers in pharmacology · 2010
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as